These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37006984)

  • 1. Economic Evaluation of Nucleic Acid Testing for Screening of Blood Donations for Thalassemia Patients (ECONAT) in Western India.
    Anne PB; Gupta A; Misra S; Sharma SK; Garg MK; Bajpayee A; Bundas S; Bohra M; Asirvatham V
    Indian J Hematol Blood Transfus; 2023 Apr; 39(2):317-324. PubMed ID: 37006984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleic acid testing for blood banks: an experience from a tertiary care centre in New Delhi, India.
    Agarwal N; Chatterjee K; Coshic P; Borgohain M
    Transfus Apher Sci; 2013 Dec; 49(3):482-4. PubMed ID: 23541414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
    Custer B; Janssen MP; Hubben G; Vermeulen M; van Hulst M
    Vox Sang; 2017 Aug; 112(6):526-534. PubMed ID: 28597489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusion transmitted infections in thalassaemics: need for reappraisal of blood screening strategy in India.
    Shyamala V
    Transfus Med; 2014 Apr; 24(2):79-88. PubMed ID: 24605952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Using Nucleic Acid Amplification Test to Screen Blood Donors for Hepatitis B, Hepatitis C, and HIV: A Tertiary Care Hospital Experience From Pakistan.
    Ali SM; Raza N; Irfan M; Mohammad MF; Kazmi FH; Fatima Z
    Cureus; 2023 Jan; 15(1):e34216. PubMed ID: 36852365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.
    Mafirakureva N; Mapako T; Khoza S; Emmanuel JC; Marowa L; Mvere D; Postma MJ; van Hulst M
    Transfusion; 2016 Dec; 56(12):3101-3111. PubMed ID: 27696441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleic acid amplification test: Bridging the gap in blood safety & re-evaluation of blood screening for cryptic transfusion-transmitted infection among Indian donors.
    Datta S; Khillan K; Ranjan V; Wattal C
    Indian J Med Res; 2019 Mar; 149(3):389-395. PubMed ID: 31249205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safety.
    Kumar R; Gupta S; Kaur A; Gupta M
    Asian J Transfus Sci; 2015; 9(2):199-202. PubMed ID: 26420945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An assessment of differences in costs and health benefits of serology and NAT screening of donations for blood transfusion in different Western countries.
    Janssen MP; van Hulst M; Custer B;
    Vox Sang; 2017 Aug; 112(6):518-525. PubMed ID: 28639703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands.
    Borkent-Raven BA; Janssen MP; van der Poel CL; de Wit GA; Bonsel GJ; van Hout BA
    Transfusion; 2009 Feb; 49(2):311-9. PubMed ID: 19389213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015).
    Fiedler SA; Oberle D; Chudy M; Scheiblauer H; Henseler O; Halbauer J; Heiden M; Funk M
    Vox Sang; 2019 Jul; 114(5):443-450. PubMed ID: 31012114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removing hepatitis C antibody testing for Australian blood donations: A cost-effectiveness analysis.
    Cheng Q; Hoad VC; Roy Choudhury A; Seed CR; Bentley P; Shih STF; Kwon JA; Gray RT; Wiseman V
    Vox Sang; 2023 Jun; 118(6):471-479. PubMed ID: 37183482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Need for nucleic Acid testing in countries with high prevalence of transfusion-transmitted infections.
    Jain R; Aggarwal P; Gupta GN
    ISRN Hematol; 2012; 2012():718671. PubMed ID: 23008779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptation of a Public-Private Partnership Model for the Implementation of Minipool Nucleic Acid Testing for Screening Routine Blood Donations and Assay Evaluation.
    Mahapatra S; Parida P; Prasad CR; Palai S; Mishra D; Behera S; Mishra RK; Prusty BP; Sarkar K
    J Lab Physicians; 2022 Sep; 14(3):317-323. PubMed ID: 36119411
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.
    Jarvis LM; Dow BC; Cleland A; Davidson F; Lycett C; Morris K; Webb B; Jordan A; Petrik J
    Vox Sang; 2005 Oct; 89(3):128-34. PubMed ID: 16146504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review.
    Wu D; Feng F; Wang X; Wang D; Hu Y; Yu Y; Huang J; Wang M; Dong J; Wu Y; Zhu H; Zhu F
    BMC Infect Dis; 2022 Mar; 22(1):279. PubMed ID: 35321684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.
    O'Brien SF; Yi QL; Fan W; Scalia V; Kleinman SH; Vamvakas EC
    Transfusion; 2007 Feb; 47(2):316-25. PubMed ID: 17302779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing.
    Fang CT; Field SP; Busch MP; Heyns Adu P
    Vox Sang; 2003 Jul; 85(1):9-19. PubMed ID: 12823725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations.
    Jackson BR; Busch MP; Stramer SL; AuBuchon JP
    Transfusion; 2003 Jun; 43(6):721-9. PubMed ID: 12757522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].
    Pillonel J; Laperche S; ; ;
    Transfus Clin Biol; 2004 Apr; 11(2):81-6. PubMed ID: 15120104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.